Market news

Henry Schein has delivered a 30.7% share price gain over the past year, which naturally puts the spotlight on whether that move is backed by the cash the business is expected to generate. With the stock recently closing at US$86.37, the key issue now is how that price lines up against the value suggested by its cash flows. The 30.7% return over the past 12 months raises a straightforward question for holders and potential buyers: whether the cash that Henry Schein can produce is enough to...

Henry Schein (NASDAQ:HSIC) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and

Henry Schein has outperformed the Dow over the past year, and analysts are cautiously optimistic about the stock’s prospects.

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Henry Schein remains a dominant global provider of dental and medical practitioner supplies. Find out why HSIC stock is a buy.

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Henry Schein (HSIC) could produce exceptional returns because of its solid growth attributes.

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Henry Schein stock performance snapshot Henry Schein (HSIC) stock has drawn investor attention after recent share price moves, with the company reporting positive total returns over the past year and across multi year periods, alongside reported revenue and net income growth. At the latest share price of US$88.52, Henry Schein has given investors a 16.9% share price return over the past 90 days and a 29.4% total shareholder return over the past year. This suggests momentum has been building...

MD Sass, a boutique asset management firm, published its second-quarter investor update for its flagship, the “MD Sass Concentrated Value Strategy.” The letter can be downloaded here. In the first half of 2026, AI infrastructure stocks led the market, with the Russell 1000 Value increasing by 16.3%, outpacing the S&P 500 (10.2%) and Russell 1000 […]

Henry Schein has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Henry Schein delivered a positive second quarter, with results exceeding Wall Street’s expectations and earning a strong market response. Management attributed the outperformance to accelerating internal sales growth, robust gains in its global dental merchandise segment, and early benefits from value creation initiatives. CEO Frederick Lowery emphasized the company’s success in converting occasional buyers into engaged customers and highlighted strong market share gains, particularly in the U.S

Motley Fool Press Release.

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Henry Schein, Inc. reported past Q2 2026 results with sales rising to US$3,458 million and net income to US$94 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier. Importantly for long-term watchers, management also raised its 2026 total sales growth guidance, signaling greater confidence in the company’s operating initiatives and demand trends. Now we’ll examine how Henry Schein’s raised 2026 sales outlook reshapes its existing...

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Henry Schein stock has delivered a 37.5% return over the past year, yet the valuation picture is more mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate indicating the shares may be trading at a sizeable discount while earnings based multiples look closer to fair. Henry Schein's 37.5% one year return suggests investors have already priced in a meaningful improvement in the story, so additional upside may depend on how the fundamentals evolve from here. The leadership...

Henry Schein (HSIC) has an average rating of overweight and mean price target of $96.69, according t

Moby summary of Henry Schein, Inc.'s Q2 2026 earnings call

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Henry Schein (NASDAQ:HSIC) reported higher second-quarter sales, operating margins and earnings, citing accelerating internal sales growth, market-share gains in dental merchandise and early benefits from its value-creation program. The company also raised its full-year sales and adjusted earnings g

While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Henry Schein (NASDAQ:HSIC) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga

Henry Schein (HSIC) delivered earnings and revenue surprises of +4.10% and +2.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 6.7% year on year to $3.46 billion. Its non-GAAP profit of $1.27 per share was 2.5% above analysts’ consensus estimates.

MELVILLE, N.Y., August 04, 2026--Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June 27, 2026.

Henry Schein: Q2 Earnings Snapshot

Dental and medical products company Henry Schein (NASDAQ:HSIC) will be reporting results this Tuesday before the bell. Here’s what you need to know.